<DOC>
	<DOCNO>NCT03101488</DOCNO>
	<brief_summary>The study evaluate characterize tolerability safety profile single agent KN035 Chinese adult subject unresectable advanced carcinoma .</brief_summary>
	<brief_title>Study KN035 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>This open label , dose escalation study evaluate safety tolerability KN035 advance metastatic solid tumor . Six dose level plan include : 0.1 , 0.3 , 1.0 , 2.5 , 5 , 10 mg/kg/dose . Subjects assign dose level order study entry . The first cohort 1 subject receive KN035 0.1 mg/kg/dose subcutaneous ( sc ) injection every week total 4 injection ( Days 1 , 8 , 15 22 ) first 28-day cycle . For first 2 cohort ( 0.01 0.03 mg/kg/dose ) , one subject enrol cohort 1 subject experience ≥ Grade 2 drug-related adverse event first cycle , 2 additional subject enrol cohort . Thereafter , study become traditional 3+3 design 3 6 subject treat dose level subsequent dose level depend upon incidence DLTs . However , ≥ Grade 2 drug-related adverse event occur first 2 cohort , start cohort 3 , study become traditional 3+3 design 3 6 subject enrol .</detailed_description>
	<criteria>Main Subject male female ≥ 18 year ≤ 70 year age day sign informed consent , subject voluntarily agree participate give write informed consent . Subjects must histopathological diagnosis locally advance metastatic solid tumor , Subjects must fail establish standard medical anticancer therapy ( disease progression therapy intolerant therapy ) Subjects refuse standard therapy , effective treatment . Measurable disease define RECIST v1.1 . Subject must performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Life expectancy ≥ 12 week . Subject must adequate hematologic organ function . Female subject childbearing potential negative serum pregnancy test . Female subject childbearing potential male subject partner childbearing potential agree keep abstinence ( refuse heterosexual intercourse ) use one method contraception failure rate le 1 % per year start first dose study drug least 6 month last dose study therapy . Main Subject Is currently participate receive study therapy participate study investigational agent receive study therapy within 28 day first dose study drug . Subject recover CTCAE Grade 1 good adverse event due cancer therapeutic administer Subject mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 millisecond ( m ) ) , history additional risk factor torsade de pointes ( TdP , e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) , use concomitant medication prolong QT/QTc interval . Subject antineoplastic therapy within 4 week prior first dose study therapy KN035 . Subject , one year time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) substance abuse ( include alcohol ) . Subjects symptomatic ascites , pleural effusion pericardial effusion . Subject pregnant breastfeeding , expect conceive father child within project duration study . Subject know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide clinically stable least 4 week prior study entry , evidence new enlarge brain metastasis steroids least 7 day first dose KN035 . Subject know psychiatric substance abuse disorder would interfere cooperation requirement trial . Subject Leptomeningeal disease . Subject previously severe hypersensitivity reaction treatment another mAb Subject active infection ( CTCAE≥Grade 2 ) 4 week first dose . Subject positive Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) , active hepatitis B hepatitis C tuberculosis . Subject receive receive live vaccine within 4 week prior first administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>KN035</keyword>
	<keyword>phase 1</keyword>
</DOC>